Phio Pharmaceuticals Establishes New At-the-Market Equity Program
at www.tipranks.com (Wed, 8-Apr 5:15 PM)
PHIO’s PH-762 Posts Strong Safety Results and High Response Rate in Skin Cancer Trial—What Does This Mean for the Future?
Market Chameleon (Wed, 11-Feb 10:33 AM)
PHIO Phase 1b Trial: Positive Safety Findings and 85% Response Rate Highlight Potential of PH-762 in Skin Cancer
Market Chameleon (Tue, 10-Feb 9:52 AM)
